ABSTRACT: Over the last several years, a clearer understanding has developed of the genetic alterations underlying thyroid carcinogenesis. This knowledge can be used to tackle 1 of the challenges facing thyroidologists: management of the indeterminate thyroid nodule. Despite the accuracy of fine-needle aspiration cytology, many patients undergo surgery to diagnose malignancy and better diagnostic tools are required. A number of biomarkers have recently been studied and show promise in this setting. In particular, BRAF, RAS, PAX8-PPARc, microRNAs, and loss of heterozygosity have each been demonstrated as useful molecular tools for predicting malignancy and can potentially guide decisions regarding surgical management of nodular thyroid disease. This review summarizes the current literature surrounding each of these markers, highlights our institution's prospective analysis of these markers, and describes the subsequent incorporation of molecular markers into a management algorithm for thyroid nodules. Palpable thyroid nodules are a relatively common finding, detected in 4% to 7% of North American adults; only about 5% of these will harbor a malignancy.
Palpable thyroid nodules are a relatively common finding, detected in 4% to 7% of North American adults; only about 5% of these will harbor a malignancy. 1 Fine-needle aspiration (FNA) biopsy is highly sensitive and is the initial invasive test of choice for identifying malignancy (Table 1) ; however, the biopsy can also show results that are indeterminate (10% to 15%) or nondiagnostic (5% to 15%) 2, 3 and surgical excision is often necessary to obtain a definitive diagnosis. Although the risks of surgery are low in experienced hands, they do occur, making any adjunct to help diagnose malignancy an attractive option.
There are a number of patient history and physical examination characteristics that clinicians currently use to predict malignancy. Patients with thyroid nodules who are at extremes of age (<20 or >70 years), male, have a history of head and neck irradiation, or a positive family history of thyroid cancer are at increased cancer risk. A nodule that on physical exam is firm, fixed to surrounding structures, associated with regional lymphadenopathy or is associated with hoarseness or dysphagia is also a concern.
Papillary thyroid cancer, in particular, has distinctive ultrasonographic features, including microcalcifications, intranodular vascularity, irregular borders, hypoechogenicity, a taller-than-wide shape, and a predominantly solid consistency. 4 Papini and colleagues 5 evaluated the ultrasound characteristics of 402 nodules by multivariate logistic regression analysis and found that irregular or blurred nodular margins (relative risk [RR] ¼ 16.83), an intranodular vascular pattern (RR ¼ 14.29), and microcalcifications (RR ¼ 4.97) were independent risk factors for malignancy. Another group retrospectively assessed the ultrasonographic features of over 1200 thyroid nodules in 580 patients, all imaged by a single radiologist, and found that the presence of at least 1 feature (microcalcifications, irregular or microlobulated margins, marked hypoechogenicity, or a taller-than-wide shape) could be used to classify a lesion as malignant with 87% sensitivity, 87% specificity, and 87% accuracy. 6 Thyroid nodule characterization by ultrasound is now considered routine. A patient with papillary thyroid cancer and a preoperative ultrasound demonstrating these suspicious nodule characteristics, including hypoechogenicity, microcalcifications, irregular border, and a taller-than-wide shape, is shown in Figure 1 .
Nodule size is also a risk factor for malignancy. Initially prompted by the high (17%) false-negative rate for benign FNA results in nodules >3 cm in size reported by Meko et al, 7 we investigated nodule size of !4 cm as an independent criterion for diagnostic lobectomy. 8 After examining the histologic findings in 223 patients who underwent thyroidectomy with a nodule !4 cm as an independent operative indication, we found that 19% of those nodules were thyroid cancer on final pathology. Of the nodules diagnosed as a follicular or Hürthle cell neoplasm on FNA, 33% (8/24) and 38% (3/8), respectively, were malignant on final pathology and, perhaps most provocatively, 24/71 patients (34%) who had benign cytology ultimately had a follicular neoplasm histologically (follicular adenoma, follicular carcinoma, and follicular variant papillary carcinoma). Among many studies of FNA accuracy, this investigation was unusually informative in design because all patients presenting with a 4-cm thyroid mass underwent thyroidectomy allowing histologic review. Overall, a false-negative rate of 13% for cancer was observed in preoperative FNA of !4-cm nodules incorrectly read as benign.
Size was also a component of the predictor model developed by Banks et al 9 to aid in the diagnosis of suspicious or indeterminate FNA samples. They first evaluated 468 patients, comparing FNA results to the final surgical histopathology and clinical characteristics with univariate analysis, which indicated that extremes of age (3% and 3.4% increased risk for each year < and >50 years of age, respectively), nodule size (53% and 39% increased risk for each centimeter < and >2.5 cm, respectively), and cytopathology (suspicious for papillary thyroid carcinoma had the greatest risk) were significant predictors of thyroid cancer. These 3 variables remained significant on multivariate analysis and, in combination, were predictive with 74% accuracy, and the findings were then validated when the model was prospectively applied to 135 new patients. 9 This was a very nicely done study, although the predictor model failed to identify all of the cancers.
The large (!4 cm) nodule size in Hürthle (oncocytic) cell neoplasms has been shown in a number of studies to have a high risk of malignancy. Zhang and colleagues 10 reviewed 55 consecutive patients who underwent thyroid surgery for a Hürthle cell neoplasm and although 44% of the lesions >4 cm were malignant, only 18% of those 2 to 4 cm in size were carcinoma. Similarly, a recent report from Sippel et al 11 evaluated 57 patients with a preoperative FNA with cytology diagnostic for a Hürthle cell neoplasm and found that the risk of malignancy increased from 13% to 55% once tumors reached >4 cm. Because of these studies, the 2009 American Thyroid Association (ATA) Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer recommend an initial total or near-total thyroidectomy for >4-cm nodules with FNA biopsy results in the indeterminate category (follicular or Hürthle cell neoplasm). 12 Diagnosis of the rare and more aggressive anaplastic or poorly differentiated thyroid cancers is less problematic. However, differentiated thyroid cancer (DTC) is increasing in incidence and an accurate diagnosis is important. Unfortunately, no patient, physical exam, radiographic, or FNA biopsy characteristic has provided a perfect tool for prediction of DTC in thyroid nodules deemed indeterminate on FNA, and many patients continue to require diagnostic thyroidectomy. In the last several years there has been significant interest in evaluating biomarkers as a potential diagnostic tool for thyroid nodules. This review summarizes the current body of literature regarding the use of what we consider to be a few of the most promising molecular markers in predicting DTC in thyroid nodules.
BRAF
BRAF is an oncogene that is implicated in a number of human cancers. It has been well established that the development of papillary thyroid cancer (PTC) involves the activation of the mitogen-activated protein kinase (MAPK) signaling pathway, and BRAF is a strong activator of that pathway. 13 A point mutation resulting in a valine to glutamate alteration at codon 600 (V600E) has been reported in up to 80% of papillary thyroid cancers. 14 BRAF mutations are also found in thyroid lymphomas, anaplastic and poorly differentiated thyroid cancers, but not in follicular or medullary carcinomas of the thyroid (MTCs) and only rarely reported in benign hyperplastic nodules. 15 Not only is the BRAF V600E mutation strongly linked to PTC, but there is evidence that it is also a marker of poorer prognosis. Multiple (but not all) reports have demonstrated an association between this mutation and established clinicopathologic parameters considered to represent aggressive tumor behavior including local recurrence, extrathyroidal extension, multicentricity, lymph node and distant metastases, and advanced TNM classification. 16, 17 Elisei and colleagues 18 retrospectively evaluated a small cohort of patients with PTC with median follow-up of 15 years and demonstrated a statistically significant decreased survival in the group carrying the V600E mutation, which also served as an independent predictor of poorer prognosis after multivariate analysis. Now that BRAF mutation has been established as a key genetic event in the evolution of papillary thyroid cancer, it begs the question of whether it has diagnostic utility and whether it can be used to optimize the surgical Forty-four of the BRAF-positive patients had undergone preoperative BRAF testing on their FNA specimens, 31 of which were positive, yielding a sensitivity of 70%. On final histopathology, all 31 patients had PTC (100% specificity), including 2 patients whose FNA biopsy results had inadequate yield but were BRAF positive. Preoperative knowledge of BRAF-positive status could have altered initial surgical management in 24% of the 75 patients in this series whose preoperative BRAF status was either unknown or falsely negative. Our group now considers BRAF-positive cytology in a dominant >1-cm nodule to be an independent indication for total thyroidectomy as initial surgery. Furthermore, BRAF status may also guide the need for and extent of initial lymphadenectomy. At present, whether routine central compartment neck dissection (CCND) is necessary for all patients with PTC remains controversial, but BRAF status may prove an important tool for guiding this decision. Proponents for more aggressive surgery to include CCND argue that although this approach does not improve overall survival, it does decrease the risk of locoregional recurrence, which can have positive effects on quality of life, as well as allowing for more accurate staging and thus a more precise assessment of the need for postoperative adjuvant therapy. 20 However, these claims have not been proven in a randomized study and future studies that include stratifying BRAF-positive and BRAF-negative patients with PTC will be informative.
Papillary microcarcinoma, or PTC <1 cm in size, is another clinical scenario where knowledge of BRAF status may prove to be useful in guiding management. At present, adjuvant therapy in the form of thyroid-stimulating hormone (TSH) suppression and radioiodine ablation is not routinely given for microcarcinoma, yet it has been shown that some of these seemingly indolent lesions can go on to develop recurrent or metastatic disease. Reported recurrence rates have varied from 3% to 17%, depending on the length of follow-up in the study and whether recurrence was defined biochemically by thyroglobulin elevation, by ultrasound evaluation, or by histopathologic confirmation after biopsy or surgery. [21] [22] [23] Documenting the presence or absence of a BRAF mutation may potentially help identify which microcarcinomas are more aggressive and therefore direct the appropriate therapeutic approach.
Resistance to the conventional adjuvant therapies used to treat PTC is thought to be 1 of the reasons why BRAFpositive PTC is associated with a poorer prognosis. In vitro studies have documented significantly lower expression levels of the sodium iodide transporter (NIS) and TSH-receptor genes in BRAF V600E-positive PTC, thereby limiting the effectiveness of radioactive iodine (RAI) ablation and TSH suppression as treatment adjuncts. 24, 25 Blocking the MAPK pathway restores expression of these genes, 26 and further studies to identify other targeted therapies are ongoing.
BRAF V600E is the most common mutation associated with PTC except in children and patients with radiationinduced PTC. In these 2 cases RET/PTC chromosomal rearrangements, which occurs exclusive of BRAF mutations, are more frequent. In the general population RET/ PTC rearrangements are seen in approximately 25% of PTC and the BRAF mutation is found in approximately 45% of PTC, although studies of post-Chernobyl PTC have documented a substantially higher prevalence of RET/PTC rearrangements (64% to 86%) and lower prevalence of BRAF mutations (5% to 16%). 27 In children with sporadic PTC, RET/PTC rearrangements are also much more common (40% to 70%) compared with BRAF mutations (0% to 12%). 28 
RAS and PAX8-PPARc
RAS is an oncogene with intrinsic GTPase activity that codes for proteins located on the inner surface of the cell membrane. When activated, RAS recruits other kinases ultimately leading to the transcription of growth and differentiation signals downstream. Point mutations lead to constitutive activation of these downstream signaling pathways and missense mutations at codons 12, 13, and 61 in K-RAS, N-RAS, and H-RAS are reported to occur in 40% to 50% of follicular carcinomas and approximately 10% of papillary thyroid carcinomas. 29 RAS mutations are identified in 48% of benign follicular adenomas as well.
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PAX8-PPARc refers to a fusion protein resulting from a balanced translocation of the peroxisome proliferator-activated receptor c gene (PPARc) and the paired box gene 8 (PAX8). The fusion protein is oncogenic, in that its formation suppresses PPARc's usual function as a regulator of transcription, but its exact role in thyroid cancer oncogenesis remains unclear. Rearrangements of PAX8-PPARc have been demonstrated in up to 63% of follicular carcinomas, but not in PTCs or follicular adenomas. 31 Nikiforova and colleagues 30 were the first to evaluate the correlation between RAS and PAX8-PPARc point mutations within follicular thyroid tumors. Of the 33 follicular thyroid carcinomas (FTCs) evaluated, 49% were RAS-positive and 36% were PAX8-PPARc-positive. Only 3% had both mutations, suggesting that RAS and PAX8-PPARc alterations are 2 separate oncogenic signals. 30 When the clinicopathologic features of the RAS-positive FTC were compared with those of the PAX8-PPARc-positive FTC, they found that the RAS-positive tumors presented later in life, were larger, and displayed a wide range of invasiveness, whereas the PAX8-PPARc-positive tumors presented at a younger age, were smaller, and the majority had overtly invasive pathology at presentation. Interestingly, Hürthle cell lesions in this study (adenomas and carcinomas) rarely exhibited either a RAS mutation or a PAX8-PPARc rearrangement, lending support to the growing body of evidence that Hürthle cell neoplasms are unique entities rather than simply a subtype of follicular lesions. The authors concluded that since 85% of conventional FTC exhibit one of these two mutations, testing FNA specimens for their presence can enhance diagnostic accuracy.
Nikiforov et al 32 recently reported results for a prospective study of 470 FNA samples from 328 consecutive patients who were tested for BRAF, RAS, PAX8-PPARc, and RET/PTC, and correlated the results of mutation status with cytology, surgical pathology, or clinical followup results. The patients were followed for a mean of 34 months. The BRAF and RAS point mutations were detected using real-time PCR and fluorescence melting curve analysis, whereas detection of RET/PTC and PAX8-PPARc rearrangements was done using reverse transcription (RT)-PCR technology. A total of 32 mutations were identified and 97% of mutation-positive nodules were papillary or follicular carcinoma on final surgical pathology. The sensitivity of molecular testing alone was 62%, but rose to 80% when combined with cytology. 32 Cantara et al 33 also reported their experience with molecular analysis of 235 FNA specimens for a panel of mutations including BRAF, RAS, RET, TRK, and PPRg, and histopathologic correlation. Mutations were identified in 28.5% of the FNA specimens and, when present, were associated with DTC 91% of the time. PTC was most commonly diagnosed, although a Hürthle cell carcinoma was also diagnosed in a patient with a RAS-positive FNA that was in the inadequate cytologic category. As a result of these studies, the recent ATA guidelines recommends consideration of using molecular markers to help guide the management of indeterminate thyroid nodules. 12 Molecular testing is also proving to be particularly helpful among thyroid lesions classified as ''follicular lesion of undetermined significance'' (FLUS). At the University of Pittsburgh Medical Center, 121 FLUS cases with molecular analysis (BRAF, RAS, RET/PTC1, and PAX8-PPARc) and available histologic correlation were reviewed. Twelve cases had positive molecular results and each of them was a papillary thyroid carcinoma on final pathology (PPV ¼ 100%). 34 All of the FLUS lesions that were RAS or PAX8-PPARc-positive (9/12) were follicular variant PTC on final pathology, and those that were BRAF-positive (3/12) were classic or tall-cell PTC on final pathology. Although the current recommendation for FLUS is to repeat the FNA, molecular testing may ultimately direct clinicians when to move directly to diagnostic surgery.
Since 2007, we have been routinely testing all FNA specimens with results in the indeterminate cytologic categories, which includes follicular or oncocytic neoplasm, nondiagnostic, suspicious, and follicular lesion of undetermined significance for a panel of biomarkers that includes NRAS61, HRAS61, KRAS12/13, BRAFV600E, RET/PTC1 and À3, and PAX8-PPARc. We have found that detection of the latter 3 in an FNA specimen correlates to a nearly 100% probability of cancer, whereas detection of RAS correlates with malignancy in 83% to 87% of cases. The majority of these RAS-positive lesions were follicular variant PTCs (unpublished data). Although RAS does not have the nearly 100% positive predictive value that BRAF has for PTC, the probability of cancer in RAS-positive indeterminate nodules is high enough that a likely diagnosis of DTC should be discussed with the patient and if the nodule is !1 cm, an up-front total thyroidectomy should be considered after adequate patient counseling. Currently at our high-volume center, molecular panel testing adds approximately $600 to the existing costs of nodule evaluation. We have observed a cost savings as a result of eliminating the need for 2-stage thyroidectomy in mutation positive patients, but a formal cost-effectiveness analysis is in process.
MicroRNAs
Recently, a class of RNAs that can function as gene expression regulators have been identified. These microRNAs (miRNAs) are small, single-stranded, noncoding RNA molecules and are important in embryonic development. There has been increasing evidence documenting their involvement in tumorigenesis as well. Decreased expression of some miRNAs may lead to oncogene upregulation and increased expression may lead to tumor suppressor gene downregulation. Since miRNAs have been implicated in cellular growth, differentiation, and apoptosis, 35 it is not surprising that aberrations in miRNA expression have been implicated in the development and progression of a number of human cancers, including lung cancer, 36 breast cancer, 37 sarcoma, 38 gastric cancer, 39 and lymphoma. 40 MiRNAs are expressed differentially depending on not only their tissue of origin but also the growth characteristics of that tissue (neoplastic vs benign), and it has been suggested that miRNA profiles may be used to determine a tumor's cellular origin.
Several recent studies have evaluated the miRNA expression profiles within different histologic types of thyroid cancer. Visone and colleagues 41 used microarray analysis to compare the miRNA expression profile of 10 human anaplastic thyroid cancers (ATCs) to 10 normal thyroid tissue samples. They discovered a significant decrease in miR-30d, miR-125b, miR-26a, and miR-30a-5p in ATC compared with the normal thyroid tissue, suggesting a ''miRNA signature'' associated with ATC. Interestingly, a downregulation of miRNAs, rather than an upregulation, has generally been found in the setting of ATC, suggesting that they function as tumor suppressor genes in undifferentiated thyroid cancer. 41, 42 Findings like these naturally prompt investigation of miRNAs as potential therapeutic targets. One study has already documented that alteration in miRNA activity can change the way tumor cells respond to chemotherapeutic agents. 43 Similar work directed at thyroid cancer holds much promise, particularly for the universally lethal anaplastic subtype for which current therapeutic options are limited.
Conversely, for PTC, studies have more commonly reported an upregulation of miRNAs. For example, Chen et al 44 reported significant overexpression of miR-221, À222, and À146b in PTC. Israel et al 45 designed a novel method of quantifying the overall effect of miRNAs on their target genes and found a global downregulation of their target genes in PTC. Regarding FTC, Weber et al 46 concluded that both miR-197 and À346 play a role in FTC carcinogenesis, after demonstrating significant overexpression of these miRNAs in FTC compared with follicular adenomas.
At our institution there has been a great deal of focus in evaluating not only the microRNA expression profiles of various thyroid neoplasms, but also on the use of miRNAs as potential diagnostic biomarkers. Nikiforova and colleagues 47 used RT-PCR to quantify expression levels of 148 miRNAs in 60 thyroid neoplasms including PTC, MTC, FTC, ATC, poorly differentiated cancers (PDCs), and follicular adenomas (FAs). In all, 32% (47/148) of the miRNAs analyzed were consistently upregulated in the neoplasms when compared with normal thyroid tissue, and 38% (57/148) were downregulated. They further identified 7 miRNAs that were consistently overexpressed in all tumors of follicular cell origin, whereas MTC had a distinct profile of highly expressed miRNAs, which is not surprising given the unique C-cell origin of these tumors. Using the subset of 7 miRNAs overexpressed in differentiated thyroid cancers, 62 FNA specimens were analyzed to determine if the panel could be a useful diagnostic adjunct to cytology and 100% of patients with cancer on final pathology showed a 2-fold overexpression of at least 1 of the miRNAs, whereas only 25% of those with a hyperplastic nodule had any significant miRNA overexpression. When >3 miRNAs in the panel were overexpressed at least 2-fold, malignancy could be predicted with 98% accuracy. 47 In summary, the discovery of miRNAs just over a decade ago is one of the most exciting developments in the field of biomarkers and holds significant promise in its application as a diagnostic tool in thyroid cancer. Further understanding of the gene targets of aberrantly expressed miRNAs may eventually lead to significant therapeutic advances for ATC, in particular.
Loss of Heterozygosity
Loss of heterozygosity (LOH) can be a key step in oncogenesis leading to a loss of tumor suppressor gene function, thereby permitting uncontrolled cell growth. Since LOH is a relatively late event in tumorigenesis, it is an attractive molecular marker for distinguishing follicular carcinoma from adenoma. LOH has been examined by several groups in follicular thyroid lesions. Grebe and colleagues 48 evaluated a cohort of FTC, PTC, and FA and LOH was considerably higher among the FTC compared with the PTC and FA, particularly on chromosomes 3p (86% vs 29% and 14%, respectively) and 17p (72% vs 22% and 0%, respectively). Another group demonstrated LOH in 67% of FTC, 40% of PTC, and 17% of FA. 49 Our institution examined 17 benign and malignant follicular neoplasms for LOH at the von Hippel Lindau (VHL) gene locus; VHL is a tumor suppressor gene that plays an important role in the evolution of both sporadic and familial endocrine tumors. DNA was extracted from each lesion and the PCR products were analyzed in a semiquantitative fashion to detect LOH at the VHL locus, which was present in 13% of follicular thyroid cancers and none of the benign follicular adenomas, and which also was strongly correlated with tumor recurrence and death. Four of the 7 cancers that recurred had LOH, whereas 3 FTCs that did not recur did not have LOH at the VHL locus. 50 A subsequent study looked at a more extensive panel of tumor suppressor genes, including VHL, p53, PTEN, p16, APC, 1p, and NF2; once again, a correlation between LOH and poor disease outcome was illustrated. 51 Fractional allelic loss (FAL) was significantly higher in the malignant compared with the benign follicular tumors (56% vs 14%, p < .001). Widely invasive follicular carcinomas had a significantly higher mean FAL compared with minimally and angioinvasive carcinomas (86% vs 44%, p ¼ .023). These studies suggest that LOH analysis of follicular neoplasm can both predict the presence of malignancy and also identify the carcinomas that may necessitate a more aggressive therapeutic strategy.
Other molecular markers
There are a number of other promising molecular markers currently under investigation. These include multiarray gene chip analysis of cDNA expression patterns 52, 53 ; multigene arrays that evaluate expression of only a select group of genes, such as cell cycle regulatory or angiogenesis modulating genes 54, 55 ; TSH receptor mRNA measurement in peripheral blood samples 56 ; and analysis of human telomerase reverse transcriptase RNA alternative splice variants. 57 Prospective validation studies are ongoing on many of these other potentially useful diagnostic adjuncts.
CONCLUSION
Management of thyroid nodular disease requires the integration and interpretation of clinical, radiographic, and cytologic variables to achieve optimal patient outcomes. A number of clinicopathologic predictors and diagnostic models have been identified, but none has been able to predict malignancy in a thyroid nodule with 100% accuracy and, at present, a significant proportion of patients still require diagnostic surgery. To improve diagnostic accuracy, a number of biomarkers have recently been evaluated and hold much promise. This review has outlined the current understanding of what we believe to be the most promising markers (Table 2 ). We present in Figure 2 a proposed management algorithm for use of molecular markers in thyroid nodule diagnosis. These molecular markers also provide exciting possibilities for targeted therapeutics in the management of thyroid cancer. 
